CD Genomics' Lentiviral/Retroviral Integration Site Sequencing provides detailed mapping of integration sites within the host genome using advanced sequencing technologies. We deliver high-resolution data and thorough bioinformatics analysis to accurately identify integration locations, offering insights into viral vector interactions with the genome. Our service supports both lentiviral and retroviral vectors, providing dependable results for research and application development.
Integration site analysis of lentiviruses delves into the precise identification and characterization of where lentiviral vectors incorporate their genetic material within the host genome. Lentiviruses, such as HIV-1, are often leveraged as gene delivery systems owing to their remarkable ability to achieve stable integration into the host genome.
The integration process initiates with the conversion of lentiviral RNA genomes into DNA through reverse transcription. Once this new DNA is synthesized, it embeds into the host's genome. While the integration process is generally random, the specific genomic context of the host cell holds sway over where integration may occur. The crux of these integration sites lies in their potential to considerably influence gene expression and cellular phenotype, underscoring the necessity to thoroughly assess their safety and efficacy within the context of gene therapies.
Retroviral integration is a complex and intricately regulated process, characterized by several pivotal phases:
Our cutting-edge platform delivers exceptionally precise sequencing of lentiviral and retroviral integration sites via the Illumina platform. Through the robust capabilities of next-generation sequencing (NGS) paired with targeted sequence capture, we achieve exact pinpointing and thorough analysis of viral vector integration within infected cells. This all-encompassing service covers every step of the process—from primer design and library construction to paired-end sequencing and intricate bioinformatics analysis—guaranteeing that the data we generate is of superior quality and utmost reliability.
What Can We Do:
1. Identification of lentiviral/retroviral integration sites in your lentiviral/retroviral infected cells.
2. Quantification of the numbers and types of gene-modified cell clones.
3. Monitor experiments using insertional mutagens and mechanistic studies of DNA integration.
Note: Our service is for research use only, not for disease diagnosis or treatment.
Detectable Objects:
Any retroviral infected cells.
Figure 1. The high-throughput sequencing analysis process.
Sequencing Platform | Sequencing Strategy | Data Volume |
---|---|---|
Illumina Hiseq/NovaSeq | PE150 |
|
Our bioinformatics analysis pipeline is flexible to your needs.
Pipeline | Analysis Content |
---|---|
Read mapping | Sequence quality filtering, trimming of DNA sequences, align sequence data to the genome of interest, identification of junction reads. |
Integration site calling | Identification and annotation of lentiviral integration sites, visualization of integration site datasets. |
Estimation of clonal abundance | Estimation of clonal abundance using the IntSiteDB database that contains genomic locations of integration sites, PCR breakpoints, and their counts. |
Custom analyses | Other bioinformatics analyses are available upon your request, such as the comparison with oncogene annotation. |
Note: The above content includes only a portion of the bioinformatics analysis. For more information or to customize the analysis, please contact us directly.
Sample Type | Quantity | Concentration | OD260/OD280 |
---|---|---|---|
Genomic DNA | ≥100 ng | ≥10 ng/μl | 1. 8 - 2. 0 |
Note:
Partial results of our Lentiviral/Retroviral Integration Site Sequencing service are shown below:
Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels
Journal: Proceedings of the National Academy of Sciences
Impact factor: 9.661
Published: February 24, 2020
Background
Cancer immunotherapy with CAR-T cells often faces challenges with T cell persistence and efficacy. The EpiVIA assay addresses this by simultaneously mapping lentiviral integration sites and chromatin accessibility at single-cell resolution. It uses Tn5 transposase to insert sequencing adapters into viral-host DNA fragments, revealing integration sites with high accuracy. This method shows CAR-T integrations favoring specific genomic regions and provides insights into T cell behavior and treatment durability.
Materials & Methods
Sample preparation:
Method:
Data Analysis:
Results
EpiVIA detects CAR-T integration sites at the single-cell level effectively. In a study of 5,000 CD8+ T cells, it identified 193 unique integration sites. Higher sequencing depth improved detection sensitivity, with more fragments per cell enhancing the ability to identify integration events.
EpiVIA's analysis of CAR-T integration sites reveals that 60% occur in transposable elements, predominantly Alu repeats, and are enriched in intronic regions. Integration sites identified by EpiVIA closely align with known HIV-1 integration sites and recurrent integration genes (RIGs). The analysis confirms EpiVIA's accuracy and highlights its ability to detect integration hotspots at a single-cell resolution.
Fig 1. Genomic features of EpiVIA identified integration sites in single cells.
Conclusions
EpiVIA is a tool for profiling both epigenomes and lentiviral integration sites at bulk and single-cell levels. It accurately maps integration sites, cell fate, and chromatin accessibility, overcoming limitations of existing methods.
References
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.
Please fill out the form below: ×